8-K - United Therapeutics Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

United Therapeutics announced positive results from the TETON-1 clinical study of Tyvaso for idiopathic pulmonary fibrosis, meeting its primary endpoint and demonstrating superiority over placebo.

Key Takeaways

1The TETON-1 study met its primary efficacy endpoint, showing superiority over placebo for change in absolute forced vital capacity by 130.1 mL (p<0.0001).

2Nebulized Tyvaso reduced the risk of clinical worsening and showed numerical improvement in secondary endpoints including time to first acute exacerbation of IPF.

3United Therapeutics plans to seek priority review of a supplemental New Drug Application to the FDA by the end of summer 2026 to add IPF to Tyvaso's labeled indications.

4Integrated analyses of TETON-1 and TETON-2 showed statistically significant treatment effects for the primary endpoint of change in absolute FVC by 111.8 mL (p<0.0001).

5The safety profile of nebulized Tyvaso was consistent with previous studies and known prostacyclin-related adverse events, with no new safety signals observed.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. Other Events** On March 30, 2026, United Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso ®

Other Event

9.01

. Exhibits ** (d) Exhibits: Exhibit No. | Col3: Description of Exhibit (d) Exhibits: 99.1 | Col3: Press Release dated March 30, 2026 (d) Exhibits: 104 | Col3: T

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1